Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin Pretreatment and Multiple Burrhole Therapy for Unstable Moyamoya
NCT03162588Phase 2Completed
- Sponsor
- Ajou University School of Medicine
- Start
- May 2010
- Primary completion
- Sep 2016
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epoetin alfa in Moyamoya disease and moyamoya syndrome, sponsored by Ajou University School of Medicine. Primary endpoints: modified Rankin Scale at 6 months and Transdural Arteriogenesis at 6 months. Started May 2010; status: completed.
02
Drugs
epoetin alfa
03
Conditions
Moyamoya diseasemoyamoya syndrome
Beyond the preview
Go deeper on NCT03162588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03162588.